Overview

• Indaptus Q3 2025 EPS beats analyst expectations, improving from last year's loss

• Company raised $2.3 mln through at-the-market facility, strengthening balance sheet

• Research and development expenses increased due to Phase 1 study costs

Outlook

• Indaptus expects current cash to support operations into Q1 2026

• Company is evaluating financing options to support its strategy

• Indaptus pauses trial enrollment pending further efficacy evaluations

Result Drivers

• BALANCE SHEET STRENGTHENED - Raised $2.3 mln through at-the-market facility

• R&D EXPENSES - Increase due to Phase 1 study costs

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "buy"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Indaptus Therapeutics Inc is $25.00, about 89.1% above its November 11 closing price of $2.72

Press Release: ID:nGNXxXz2j

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)